Levetiracetam Vitória

Levetiracetam, the active ingredient in Levetiracetam Vitória, is an anticonvulsant presented as an oral dosage form for oral use. It is employed to control various seizure types in patients with epilepsy, including partial‑onset, generalized tonic‑clonic and myoclonic seizures.

GNH USA supplies Levetiracetam Vitória as a licensed, GDP‑compliant international pharmaceutical supplier, providing EU‑sourced products to hospitals, pharmacies and clinics worldwide. Our distribution network follows stringent quality and regulatory standards to ensure reliable access across multiple regions.

Levetiracetam is an antiepileptic drug that acts on neuronal excitability to reduce seizure activity.

Partial‑onset seizures: helps achieve seizure control and reduces frequency of focal events. Generalized tonic‑clonic seizures: contributes to overall seizure reduction and improves patient stability. Myoclonic seizures: diminishes the occurrence of rapid, involuntary muscle jerks associated with this seizure type.

Levetiracetam may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: generalized tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Depression: new or worsening mood disorders. - Blood dyscrasias: rare cases of leukopenia or thrombocytopenia. - Severe allergic reactions: anaphylaxis or angioedema. - Multi‑organ hypersensitivity: systemic inflammatory response involving multiple organ systems.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Concomitant CNS depressants: may enhance sedation or respiratory depression. - Pregnancy: safety data are limited; weigh potential benefits against unknown risks. - Pediatric use: safety and efficacy have not been fully established in children. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing levetiracetam plasma levels. - Phenytoin: increases hepatic enzyme activity, decreasing drug exposure. - Rifampin: strong enzyme inducer that markedly lowers levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring observation. - CNS depressants (e.g., benzodiazepines): additive sedative effects. - Alcohol: enhances central nervous system depression and may worsen side effects.